NCT00287872View on ClinicalTrials.gov

Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Multiple Myeloma
Interventions
DRUG

bortezomib

DRUG

thalidomide

Trial Locations (1)

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00287872 - Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma | Biotech Hunter | Biotech Hunter